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Abstract
Introduction: Male breast cancer (MBC) is a rare and inadequately characterized disease. The aim of the present
study was to characterize MBC tumors transcriptionally, to classify them into comprehensive subgroups, and to
compare them with female breast cancer (FBC).
Methods: A total of 66 clinicopathologically well-annotated fresh frozen MBC tumors were analyzed using Illumina
Human HT-12 bead arrays, and a tissue microarray with 220 MBC tumors was constructed for validation using
immunohistochemistry. Two external gene expression datasets were used for comparison purposes: 37 MBCs and
359 FBCs.
Results: Using an unsupervised approach, we classified the MBC tumors into two subgroups, luminal M1 and
luminal M2, respectively, with differences in tumor biological features and outcome, and which differed from the
intrinsic subgroups described in FBC. The two subgroups were recapitulated in the external MBC dataset. Luminal
M2 tumors were characterized by high expression of immune response genes and genes associated with estrogen
receptor (ER) signaling. Luminal M1 tumors, on the other hand, despite being ER positive by
immunohistochemistry showed a lower correlation to genes associated with ER signaling and displayed a more
aggressive phenotype and worse prognosis. Validation of two of the most differentially expressed genes, class 1
human leukocyte antigen (HLA) and the metabolizing gene N-acetyltransferase-1 (NAT1), respectively, revealed
significantly better survival associated with high expression of both markers (HLA, hazard ratio (HR) 3.6, P = 0.002;
NAT1, HR 2.5, P = 0.033). Importantly, NAT1 remained significant in a multivariate analysis (HR 2.8, P = 0.040) and
may thus be a novel prognostic marker in MBC.
Conclusions: We have detected two unique and stable subgroups of MBC with differences in tumor biological
features and outcome. They differ from the widely acknowledged intrinsic subgroups of FBC. As such, they may
constitute two novel subgroups of breast cancer, occurring exclusively in men, and which may consequently
require novel treatment approaches. Finally, we identified NAT1 as a possible prognostic biomarker for MBC, as
suggested by NAT1 positivity corresponding to better outcome.
* Correspondence: Ingrid.Hedenfalk@med.lu.se
1Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B,
SE 22185 Lund, Sweden
Full list of author information is available at the end of the article
Johansson et al. Breast Cancer Research 2012, 14:R31
http://breast-cancer-research.com/content/14/1/R31
© 2012 Johansson et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Introduction
Male breast cancer (MBC) is a rare cancer form
accounting for only 0.6% of all breast cancer cases in
the Nordic countries [1]. MBC is similar to female
breast cancer (FBC) in many ways and is often likened
to post-menopausal breast cancer in women due to the
high prevalence of estrogen receptor (ER) positivity and
relatively high age at onset. There are nevertheless also
distinct differences; there is an ongoing debate regarding
the level of similarity between FBC and MBC, and
whether MBC may be a unique tumor type with biologi-
cal features and clinicopathological parameters distinct
from FBC [2-4]. MBC tumors are more frequently hor-
mone receptor positive than FBC tumors (ER positivity
91% vs. 76% and progesterone receptor (PR) positivity
81% vs. 67%, respectively). Human epidermal growth
factor receptor 2 (HER2) over-expression and/or ampli-
fication appear less frequent in MBC and the mean age
at diagnosis is approximately five years older than for
women [2,3,5,6]. Risk factors include hormonal imbal-
ances (for example, caused by liver disease, Klinefelter’s
syndrome or obesity), genetic predisposition (mainly due
to BRCA2 mutations) and environmental factors (for
example, exposure to chronic heat or radiation) [7,8].
Survival rates have been debated, with some studies
finding that men diagnosed with breast cancer have a
worse prognosis than women [9,10], whereas other stu-
dies have reported similar prognoses [11,12]. The rarity
of the disease has, however, precluded randomized trials
for optimizing patient management; thus, recommenda-
tions for treating MBC are extrapolated from small ret-
rospective trials and prior knowledge of FBC [13].
Importantly, no major progress has been made in the
treatment of MBC since the introduction of hormonal
therapy; survival rates have not improved over the last
decades, unlike the female counterpart. Refined, com-
prehensive classification and identification of novel bio-
markers will greatly increase our understanding of the
pathobiology of the disease, and enable personalized
clinical management as well as rationales for targeted
therapy. We have previously described two genomic
subgroups of MBC by array-based comparative genomic
hybridization (aCGH) [14], and a few smaller studies
have described specific differences between MBC and
FBC based on gene expression (GEX) [15], microRNA
[16,17] and genomic profiles [14,18], respectively.
In the present study, we aimed to understand MBC on
the transcriptional level and to subclassify tumors into
comprehensive subgroups. We also wanted to further
validate the previously identified genomic subgroups
that were based on the same cases [14], and to compare
MBC with FBC. To this end, molecular profiling has
been extensively applied to FBC by numerous
independent researchers, resulting in the subdivision
into gene expression-based ‘intrinsic’ subgroups asso-
ciated with differences in survival as well as biological
phenotypes [19-22]. Herein, we describe two stable sub-
groups of MBC, luminal M1 and luminal M2, respec-
tively, highly correlated to the recently described MBC
genomic subgroups [14]. Remarkably, these subgroups
were distinct from the well-established intrinsic sub-
groups of FBC, and may, as such, represent unique sub-
types of breast cancer arising exclusively in males. The
largest subgroup (luminal M1), comprising two-thirds of
all cases, displayed a more aggressive phenotype and
worse prognosis compared to the other cases, while
high expression of immune response and ER-related
genes was seen in the smaller subgroup (luminal M2).
Finally, we identified N-acetyltransferase-1 (NAT1) as a
potential prognostic biomarker in MBC.
Materials and methods
Tumor tissue
All cases of MBC diagnosed between 1983 and 2009 in
the Lund and Uppsala-Örebro regions with sufficient
tumor material available were identified. Fresh frozen
and paraffin-embedded primary tumors were obtained
from the Southern Sweden Breast Cancer Group’s tissue
bank at the Department of Oncology, Skåne University
Hospital, Uppsala University Hospital and Örebro Hos-
pital. A physician (CN) reviewed all patient charts and
collected clinicopathological data. A pathologist (ST)
graded all tumors to current pathological standard; all
histological grades were represented. ER, PR and HER2
were re-evaluated (see [6] for further details). The
patients had received different combinations of adjuvant
treatment, including hormonal, chemotherapy and radia-
tion treatment, and the mean follow-up time was 4.6
years (range 0.04 to 15 years). The mean age at diagno-
sis was 70 years (range 23 to 98). Five known BRCA2
mutation carriers, but no known BRCA1 mutation car-
riers, were included; however, most of the patients were
not screened for BRCA1/2 mutations. The clinocopatho-
logical data are summarized in Table 1 and a flow chart
illustrating the datasets used in the explorative and vali-
dation phases is provided in Additional file 1. The study
was approved by the regional Ethics Committee in
Uppsala (2007/254) waiving the requirement for
informed consent for the study.
Gene expression (GEX) analysis
Tumor cellularity was determined on H&E stained sec-
tions and only tumors with high (> 70%) tumor cell
content were included. Total RNA was extracted from
fresh frozen tumors using the RNeasy Lipid Tissue Mini
Kit (QIAGEN, Valencia, CA, USA) and RNA integrity
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Table 1 Clinicopathological data for the fresh frozen and paraffin-embedded MBC tumors, respectively
Clinicopathological characteristics Fresh frozen tumors N (%) Paraffin-embedded tumors N (%)
Age at diagnosis
Mean 69 70
Range 42 to 93 23 to 98
Tumor size
T1 18 (27) 93 (42)
T2 38 (58) 91 (41)
N/A 10 (15) 36 (16)
Node status
N0 16 (24) 83 (38)
N+ 37 (56) 78 (35)
N/A 13 (20) 59 (27)
ER status
Positive 52 (79) 193 (88)
Negative 3 (5) 9 (4)
N/A 11 (17) 18 (8)
PR status
Positive 46 (70) 160 (73)
Negative 9 (14) 41 (19)
N/A 11 (17) 19 (9)
HER2 status
Positive 2 (3) 18 (8)
Negative 35 (53) 157 (71)
N/A 29 (44) 45 (20)
BRCA2 mutation status
Positive 3 (5) 5 (2)
Negative 7 (11) 12 (5)
N/A 56 (85) 203 (92)
Histology
DCIS 1 (2) 4 (2)
Invasive cancer in combination with DCIS 14 (21) 47 (21)
Invasive cancer 43 (65) 130 (59)
N/A 8 (12) 39 (18)
NHG
I 2 (3) 15 (7)
II 17 (26) 98 (44)
III 19 (29) 85 (39)
N/A 28 (42) 22 (10)
Metastases
Yes 16 (24) 46 (21)
No 39 (59) 123 (56)
N/A 11 (17) 51 (23)
Follow-up time (years)
Mean 5.3 4.6
Range 0.20 to 15 0.04 to 15
Adjuvant chemotherapy
Yes 6 (9) 21 (10)
No 51 (77) 159 (72)
N/A 9 (14) 40 (18)
Adjuvant endocrine therapy
Yes 37 (56) 120 (55)
No 20 (30) 66 (30)
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was assessed on an Agilent 2100 Bioanalyzer (Agilent,
Santa Clara, CA, USA). RNA quantification was per-
formed using a NanoDrop ND-1000 (NanoDrop Pro-
ducts, Wilmington, DE, USA). Sixty-six samples with
RIN values ≥ 7 were hybridized to Human HT-12 v3.0
Expression BeadChips (Illumina Inc, San Diego, CA,
USA) in three batches at the SCIBLU Genomics Center
at Lund University. Data normalization and manage-
ment were performed using BioArray Software Environ-
ment (BASE) [23] and R [24]. Data were normalized
using quantile normalization in BASE and were there-
after log2 transformed. To handle potential platform
related biases, four samples each from hybridization
batches one and two were re-hybridized in the third
batch, resulting in a total of 74 experiments. A principal
component analysis (PCA) was run and associations
between principal components and technical and biolo-
gical annotations were evaluated, whereupon a batch
effect was detected as the main principal component
(Additional file 2A). To correct for technical biases a
supervised empirical Bayes method (ComBat) was thus
applied [25]. PCA was then carried out on ComBat cor-
rected data, whereupon no technical variation was found
among the main principal components (Additional file
2B). The gene expression data have been published in
NCBI’s Gene Expression Omnibus (GEO) database
(GSE31259) [26].
Unsupervised discovery of MBC GEX subgroups
Probes with low signals (mean < 5.8 across all experi-
ments) were filtered away and probes that varied the
most across experiments were selected for use in unsu-
pervised hierarchical clustering (HCL). Probes were
mean centered across experiments. Pearson correlation
distance and complete linkage were used for HCL. To
assess the robustness of the initial HCL analysis, a mul-
tiscale bootstrap resampling was performed on the
probes using the R-package Pvclust [27]. To further vali-
date the stability of the clusters, resampling was per-
formed on the samples to obtain 10,000 bootstrapped
datasets. The co-clustering frequencies of sample pairs
across the datasets were calculated. HCL was then car-
ried out on the co-clustering frequencies and the den-
drogram clusters were compared with the clusters from
the initial HCL analysis as described [28]. When stable
clusters were detected the procedure was repeated for
each subcluster until no more stable clusters could be
detected.
Gene ontology
The Illumina probes were re-annotated using Re-anno-
tation and Mapping for Oligonucleotide Array Technol-
ogies (ReMOAT) [29], and for the ontology studies only
probes with good or perfect quality were used. A two-
class unpaired significance analysis of microarray (SAM)
was performed for MBC subgroups to identify differen-
tially expressed genes, and the false discovery rate (FDR)
0 was used as a cut-off for significance. Up- and down-
regulated genes were run separately in the database for
annotation, visualization and integrated discovery
(DAVID) v6.7 to identify possible enrichment of genes
with specific biological themes separating the subgroups
[30,31].
Module signatures from FBC
Seven GEX modules associated with key biological pro-
cesses in FBC (tumor invasion and metastasis, immune
response, angiogenesis, apoptosis, proliferation, and ER
and HER2 signaling, respectively) were used to discover
biologically meaningful differences between MBC sub-
groups and to compare them with the intrinsic sub-
groups of FBC [21,32]. A score was computed for each








where xi is the expression of gene i in the module and
wi is either +1 or -1 depending on the up- or down-reg-
ulation of each gene in the original FBC study [32]. The
module scores were also calculated for a reference
Table 1 Clinicopathological data for the fresh frozen and paraffin-embedded MBC tumors, respectively (Continued)
N/A 9 (14) 34 (15)
Post-operative radiotherapy
Yes 30 (45) 85 (39)
No 28 (42) 96 (44)
N/A 8 (12) 39 (18)
Surgery
Mastectomy 58 (88) 178 (81)
Lumpectomy 1 (2) 12 (5)
No surgery 0 (0) 2 (1)
N/A 7 (11) 28 (13)
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dataset representing all subgroups of FBC [22] as well as
for an external dataset of MBC [15].
Independent validation and comparison with FBC using
external datasets
An external GEX dataset on custom made cDNA micro-
array slides containing 16,457 sequence-verified I.M.A.G.
E. clones (Research Genetics, Invitrogen, Carlsbad, CA,
USA) with 37 MBCs was downloaded from ArrayEx-
press (ID: E-TABM-810) [15]. Data quality assessment
and normalization were performed in R [24]. Limma
packages were used for background correction; a within-
array method for data centering followed by a between-
array method using quantile normalization. A normal-
ized FBC dataset containing 359 FBC samples represent-
ing all intrinsic subgroups was downloaded from GEO
(GSE22133) [22,26]. Samples in the validation sets were
classified into MBC subgroups using nearest centroid
classification. Centroids were calculated in our MBC
data using the top 124 genes from the SAM analysis.
Samples were classified based on to which centroid they
showed the highest correlation and were unclassified if
the correlation was < 0.2. We also performed nearest
centroid classification for the intrinsic subgroups of FBC
using the genes from Hu et al. on the MBC samples in
our study as well as the MBC validation samples [21].
The Hu classifier relies on expression levels relative to
the spectrum of FBC, that is, including both ER negative
(ER-) and positive (ER+) samples. Since the vast major-
ity of MBCs are ER+, we constructed an ER+ specific
FBC subtype classifier. Briefly, ER+ samples were
extracted from the FBC reference dataset and genes
were mean centered across these samples. A SAM ana-
lysis was performed between the luminal A and B sam-
ples among these ER+ FBC samples, whereupon 300
significant genes with FDR = 0 were selected. Centroids
were calculated for luminal A and B tumors separately
using these 300 genes. Both MBC datasets were classi-
fied using these ER+ FBC luminal centroids. Finally, for
the MBC validation dataset, the detection of stable sub-
groups was performed using the same unsupervised
approach used for our dataset, and these subgroups
were then compared with the subgroups from the cen-
troid classification.
Validation immunohistochemistry (IHC)
A tissue microarray (TMA) with two 1 mm cores from
each of 220 MBC tumors was constructed as described
[9]. Sections of 3 to 4 μm were cut, transferred to glass
slides, dried at room temperature and then baked in a
heat chamber for two hours at 60°C. The DAKO Envi-
sion horseradish peroxidase rabbit/mouse kit (DAKO,
Glostrup, Denmark) and a Dakocytomation Autostainer
(DAKO) were used for the staining procedure. A
monoclonal mouse antibody to the polymorphic heavy
chain of human MHC Class I (HC10, diluted in 1:1,000
in high pH), with preferential binding to HLA-B and
HLA-C alleles and some HLA-A was generously pro-
vided by Prof. Dr. J. Neefjes [33,34], and the primary
NAT1 antibody (diluted 1:1,000 in low pH) has been
previously described [35,36]. The evaluation of NAT1
and HLA was performed by one reader (IJ) in a blinded
manner. The intensity of the staining in the tumor cells
was scored on a scale as: 0 (absent), 1 (weak), 2 (moder-
ate) or 3 (strong). The percentage of positively stained
tumor cells was scored as: 0 (< 5%), 1 (5 to 25%), 2 (26
to 50%), 3 (51 to 75%) or 4 (> 75%).
Statistical analyses
All figures and statistical calculations were generated in
R [24]. For the survival analyses the survival and surv-
comp packages were used with distant metastasis free
survival (DMFS) as end-point. All P-values are two-
sided.
Results
Discovery of two stable subgroups of MBC
Unsupervised HCL on co-clustering frequencies revealed
two stable subgroups of MBC (Figure 1A, B) as did
Pvclust, where both clusters had an approximately
unbiased (AU) probability of 94% [37]. The two sub-
groups could not be further subdivided into stable
groups, perhaps due to the limited sample size. The lar-
ger subgroup (from hereon labeled luminal M1) con-
tained 46/66 (70%) tumors and the smaller subgroup
(labeled luminal M2) contained 20/66 (30%) tumors.
The subgroups displayed different GEX patterns, as well
as a tendency towards differences in age at diagnosis
(Wilcoxon test, P = 0.093, Figure 1C). There was no dif-
ference in Nottingham histological grade (NHG, Fisher’s
Exact Test, P = 1.0) or tumor size (Wilcoxon test, P =
0.26) between the subgroups. The two subgroups corre-
lated with the genomic subgroups (male-simple and
male-complex, respectively; Figure 1A) that we pre-
viously defined based on genomic aberrations within the
same patient cohort [14]; 89% of the luminal M1 tumors
were classified as male-complex and 47% of the luminal
M2 tumors were classified as male-simple (Fisher’s exact
test, P = 0.0079). Kaplan-Meier survival analysis indi-
cated better survival in the luminal M2 subgroup; the
difference in DMFS was, however, not statistically signif-
icant (P = 0.14, Figure 1D), most likely due to the lim-
ited number of events.
Differences in key biological processes between MBC
subgroups
We investigated the expression of seven GEX modules,
representing key biological processes involved in FBC
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Figure 1 Unsupervised hierarchical clustering (HCL) of male breast cancers based on 1,652 differential expressed genes. (A) HCL
revealed two stable subgroups, luminal M1 (right) and luminal M2 (left). Annotations with the prefix Hu indicate the result of the centroid
classification based on the Hu genes [21]. Annotations with the prefix cent were derived from the centroid classification with the genes for ER+
luminal female breast cancer (FBC). NHG, Nottingham histological grade. (B) Unsupervised HCL based on co-clustering frequencies revealed two
stable subgroups. Co-clustering frequencies close to 1 are red, close to 0 are green and equal to 0.5 are black. (C) Difference in age at diagnosis
between the subgroups. (D) Kaplan-Meier survival analysis suggesting better distant metastasis free survival (DMFS) in the luminal M2 subgroup.
The numbers below the plot indicate the number of patients at risk in each group at the given time points.
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tumorigenesis [32], in the respective subgroups to better
characterize the biological foundation of MBC and the
mechanisms underlying differences between the sub-
groups. Among the seven defined modules, proliferation
(Wilcoxon test, P = 0.064), HER2 (Wilcoxon test, P =
0.0057), tumor invasion and metastasis (Wilcoxon test,
P = 1.0 × 10-5), ER signaling (Wilcoxon test, P = 1.3 ×
10-8) and immune response (Wilcoxon test, P = 0.16)
displayed significant differences or a tendency towards
differences between the two subgroups (Figure 2A).
Luminal M1 tumors appeared more highly correlated to
the tumor invasion and metastasis, proliferation and
HER2 modules than luminal M2 tumors, further sup-
porting the notion that luminal M1 tumors may be
more aggressive than luminal M2 tumors. The expres-
sion of each of the modules in the intrinsic subgroups
of FBC is shown in Figure 2B for comparison. Interest-
ingly, neither the luminal M1 nor the luminal M2
subgroup of MBC displayed patterns of module scores
resembling any of the intrinsic FBC subgroups. Of note,
even though the majority of the MBC tumors were ER+
by IHC, the module score for ER signaling differed sig-
nificantly between the subgroups (P = 1.3 × 10-8, Figure
2A). The ER+ subgroups of FBC (luminal A and B), on
the other hand, both displayed very similar module
scores for ER signaling, as expected (Figure 2B).
Gene ontology indicates that luminal M1 tumors are
more aggressive than luminal M2 tumors
A SAM analysis was performed, resulting in 544 up-regu-
lated genes and 370 down-regulated genes in the luminal
M2 compared to the luminal M1 subgroup (FDR = 0).
The up- and down-regulated genes were uploaded sepa-
rately into DAVID and some of the most relevant gene
ontology (GO) terms associated with genes up-regulated
in luminal M1 tumors included: cell migration, cell
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Figure 2 Gene expression (GEX) modules associated with key biological processes. The module scores of GEX modules representing key
biological processes involved in FBC tumorigenesis [32] in the two subgroups of MBC (A), in the intrinsic subgroups of FBC (B), and in the MBC
validation dataset (C), respectively. Proliferation (Wilcoxon test, P = 0.064), HER2 (Wilcoxon test, P = 0.0057), tumor invasion and metastasis
(Wilcoxon test, P = 1.0 × 10-5), ER (Wilcoxon test, P = 1.3 × 10-8) and immune response (Wilcoxon test, P = 0.16) displayed a significant or
borderline significant difference between the two subgroups of MBC (A). The ANOVA test was used to calculate P-values (B).
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adhesion, angiogenesis, cell cycle, cell division and HOX
genes (Additional file 3). Luminal M2 tumors, on the
other hand, displayed up-regulation of genes associated
with the GO term class I histocompatibility antigen, which
is involved in the immune system (Additional file 4).
Taken together, this suggests that luminal M1 tumors may
be more aggressive than luminal M2 tumors, and may
thus be associated with inferior outcome.
Validation of the MBC subgroups with an independent
external dataset
To further validate our discovery of two transcriptional
subgroups we used an external MBC dataset consisting
of 37 cases [15]. As a first step, we used MBC subgroup
centroids from our data to classify the validation
samples into the two subgroups, resulting in 19%
unclassified samples (with a correlation cutoff > 0.2).
When no correlation cutoffs were used, 26/37 (70%)
tumors were classified as luminal M1 and 11/37 (30%)
as luminal M2, identical to results for our dataset. In
support of this finding, when an unsupervised approach
was used to identify subgroups in the validation cohort,
we found two stable subgroups comprising 11 and 26
tumors, respectively (Figure 3B). In the first subgroup
10/11 (91%) tumors were centroid classified as luminal
M2, while in the second subgroup 25/26 (96%) tumors
were centroid classified as luminal M1. To further sup-
port the validity of the identified subgroups, a compari-
son of the GEX patterns for the subgroup-derived



































































































































Our dataset External validation dataset
Figure 3 Male breast cancer (MBC) subgroup specific genes. Validation of two stable MBC subgroups in an external dataset. The heatmaps
of the MBC subgroup-derived centroid genes revealed identical distribution frequencies and similar transcriptional profiles in our dataset (A) and
the external validation dataset (B). Red corresponds to up-regulation and green to down-regulation. The MBC sample order was derived from
the unsupervised hierarchical clustering and the annotations are from the centroid classification with the MBC subgroup-derived centroid genes.
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dataset revealed highly similar patterns (Figure 3A, B).
Finally, to additionally characterize the validation data-
set, scores for the seven FBC GEX modules were calcu-
lated, revealing correlations between the respective
modules and the two subgroups similar to our dataset
(Figure 2A, C).
The MBC subgroups differ from the intrinsic subgroups of
FBC
In an effort to identify the degree of similarity between
MBCs and the commonly used intrinsic subtypes of
FBC [19,21], we applied a centroid-based approach
based on the Hu genes to our MBC dataset. This classi-
fication left 55% of the samples unclassified. Taking into
account that MBCs are generally ER+, we also classified
the MBCs using ER+ FBC luminal subgroup centroids.
Even using this approach, 36% of the samples remained
unclassified. Conversely, when ER+ FBC samples were
classified using the MBC subgroup centroids, 151 sam-
ples (63%) were unclassified. Interestingly, luminal M1
tumors showed significantly higher correlations to the
HER2 and basal centroids (Wilcoxon test, P = 1.1 × 10-3
and P = 6.8 × 10-5, respectively), while luminal M2
tumors were significantly higher correlated to both
luminal A and B centroids (Wilcoxon test, P = 1.9 × 10-
5 and P = 0.018, respectively). Furthermore, pronounced
differences in the GEX patterns were observed when the
Hu genes and the ER+ FBC luminal subgroup centroid
genes were compared across male and female breast
cancers (Additional files 5 and 6). When the MBC
tumors were clustered with the ER+ FBC subgroup
centroid genes, the two MBC subgroups were mixed
between the main clusters found (Additional file 7).
These findings indicate that the MBC subgroups differ
substantially from the intrinsic subgroups of FBC.
NAT1 protein expression is prognostic for MBC
Based on the finding that luminal M2 tumors displayed
a higher correlation to the ER signaling module than
luminal M1 tumors (Figure 2A), we investigated the
protein expression of NAT1, one of the genes in this
module, in 220 MBCs arranged in a TMA. NAT1 was
also one of the top candidate genes from the SAM ana-
lysis, with a significantly higher expression in luminal
M2 tumors compared to luminal M1 tumors. Tumors
were considered positive for NAT1 if > 75% of the can-
cer cells showed cytoplasmic staining (Additional files
8A-C). Intense cytoplasmic staining was occasionally
accompanied by nuclear staining, but this was not con-
sidered in the evaluation. A total of 113 (51%) tumors
were NAT1 positive and 91 (41%) tumors were NAT1
negative (data were missing for 19 (8%) tumors). NAT1
protein expression correlated significantly to the mRNA
levels (Spearman correlation 0.80, P = 1.7 × 10-10). A
significant difference in the protein expression of NAT1
was seen between the subgroups, with more luminal M2
tumors being NAT1 positive compared to luminal M1
tumors (Fisher’s exact test, P = 0.018). Furthermore,
NAT1 negativity was associated with poor five-year
DMFS in the whole cohort (hazard ratio (HR) 2.5 (95%
CI 1.0 to 5.9) P = 0.033; Figure 4A). Importantly, the
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P = 5.2E-4
Figure 4 Kaplan-Meier survival analyses. Distant metastasis free survival of the 220 male breast cancer patients included in the TMA stratified
by HLA expression (A) and NAT1 expression (B), respectively. The numbers below the plots indicate the number of patients at risk in each
group at the given time points.
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remained significant in a multivariate analysis when
adjusting for node status, NHG, and tumor size (HR 2.8
(95% CI 1.0 to 7.2) P = 0.040; Table 2). To delineate
whether NAT1 may predict response to endocrine ther-
apy, we attempted to examine the association between
NAT1 and DMFS separately in tamoxifen-treated
patients; however, there were too few patients and
events in the respective groups to perform this analysis
(data not shown).
The correlation between immune response and prognosis
Significant up-regulation of immune-related genes was
observed in luminal M2 compared to luminal M1
tumors (Additional file 4), and a higher correlation to
the immune module was also seen (Figure 2A, C).
More specifically, class 1 HLA genes were strongly up-
regulated in luminal M2 tumors. To explore the prog-
nostic impact of immune-related genes we therefore
assessed the protein levels of HLA in the extended
cohort. Tumors were defined as positive, moderate or
negative when > 50%, 5 to 50% or < 5% of the cancer
cells were positive, respectively (Additional file 8D-F).
Ninety-three (42%) tumors were positive, 51 (23%) dis-
played moderate staining and 58 (26%) were negative
(data were missing for 21 (9%) tumors). A significant
difference in the protein expression was observed, with
the luminal M2 subgroup containing more HLA posi-
tive tumors than the luminal M1 subgroup (Fisher’s
exact test, P = 0.039). Most interestingly, HLA positiv-
ity was associated with significantly better DMFS than
moderate HLA expression (HR 3.6 (95% CI 1.6 to 7.9)
P = 0.002). The DMFS was similar in the HLA nega-
tive and the HLA positive groups during the beginning
of the follow-up, but late events (> 8 years) among
HLA negative cases nevertheless resulted in poor
DMFS in the latter group, comparable to the moderate
HLA group (Figure 4B).
Discussion
While it is generally accepted that FBC is a heteroge-
neous disease both in terms of transcriptional profiles,
genomic aberrations and survival [19-22], whether MBC
can be classified into comprehensive subgroups asso-
ciated with differences in clinicopathological variables
has not yet been elucidated. The inferior outcome
reported clearly indicates the requirement to better
understand the pathobiology of MBC [9], and the need
to stratify patients based on tumor characteristics,
potentially in need of alternative treatment strategies.
In this study, we have performed GEX profiling on 66
MBC tumors to study the disease transcriptionally and
to subclassify tumors based on mRNA profiles. We were
thus able to stratify tumors into two stable subgroups,
luminal M1 and luminal M2, respectively, associated
with different biological features and clinicopathological
characteristics. While additional subgroups may exist,
the sample size was too small for further subdivisions.
As evidenced from the SAM analysis, the two GEX sub-
groups displayed a large number of differentially
expressed genes. Patients tended to be diagnosed at a
younger age in the luminal M1 subgroup, but no differ-
ences in histological grade or tumor size were observed.
Interestingly, the two subgroups correlated with the
genomic subgroups (male-simple and male-complex,
respectively) that we previously defined based on geno-
mic aberrations within the same patient cohort [14].
Specifically, the luminal M2 subgroup described in the
present study contained the majority of the male-simple
tumors, while the luminal M1 subgroup harbored most
of the male-complex tumors. There was a tendency
towards better DMFS among patients with male-simple
tumors with few genomic aberrations compared to
patients with male-complex tumors with highly rear-
ranged genomes and survival comparable to luminal B
FBCs. Male-simple tumors were less frequently aneu-
ploid, displayed a lower fraction of genome altered as
well as lower S-phase fractions [14], further supporting
better outcome among patients with luminal M2 (male-
simple) vs. luminal M1 (male-complex) tumors.
To better understand the biological differences
between the two subgroups, we performed an ontology
analysis, whereupon up-regulation of genes involved in
cell migration, cell adhesion, angiogenesis, cell cycle, cell
division and HOX genes was identified among luminal
M1 tumors. Two of the well-known hallmarks of cancer
development are activation of invasion and metastasis
and induction of angiogenesis, respectively [38]. Up-reg-
ulation of genes involved in these processes in the lumi-
nal M1 subgroup indicates that these tumors may have
Table 2 Uni- and multi-variate analysis of five-year breast
cancer specific survival
Variable Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
NAT1 positive 2.5 1.0 to 5.9 0.033 2.8 1.0 to 7.2 0.040
No vs. Yes
Age 1.4 0.33 to 5.8 0.66
< 45 vs. ≥ 45
Tumor size 2.9 1.3 to 6.6 0.008 2.4 0.82 to 6.8 0.11
T2 vs. T1
Node status 3.3 1.4 to 7.9 0.005 3.1 1.1 to 8.3 0.029
Pos vs. Neg
NHG 2.3 1.1 to 5.0 0.032 0.97 0.40 to 2.3 0.95
3 vs. 1 to 2
PR positive 0.50 0.22 to 1.1 0.079
Yes vs. No
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a more aggressive phenotype than luminal M2 tumors.
HOX genes are DNA binding factors involved in the
transcriptional regulation of many key development fac-
tors, and de-regulated expression of HOX genes has
been found to be involved in carcinogenesis and metas-
tasis in many different cancer forms, including breast
cancer [39]. In the present study, HOXB7, which has
been shown to be involved in epithelial-mesenchymal
transition, migration and invasion in FBC [40], was sig-
nificantly up-regulated in luminal M1 tumors compared
to luminal M2 tumors. This finding also corresponds to
the higher frequency of distant metastases in the former
group.
An additional hallmark of cancer pertains to activation
of the immune system, specifically by T and B lympho-
cytes, macrophages and natural killer cells [38]. To this
end, luminal M2 tumors displayed high expression of
genes associated with class I histocompatibility antigens,
which are involved in regulating the immune response,
further supporting a more favorable outcome among
luminal M2 tumors. A Kaplan-Meier survival analysis
indeed suggested better DMFS among luminal M2
tumors, lending additional support to this notion.
To further understand the biological differences
between the MBC subgroups, we investigated seven key
biological processes associated with differences in survi-
val among the intrinsic subtypes of FBC by calculating
scores for each module in the two MBC subgroups. The
luminal M2 subgroup demonstrated higher scores for the
immune response and ER modules, while luminal M1
tumors displayed higher scores for the tumor invasion
and metastasis, proliferation and HER2 modules, again
indicating differences in tumor aggressiveness between
the subgroups. A surprising finding was the low score for
the ER module among luminal M1 tumors, despite
almost all MBC tumors in the present study being ER+.
In FBC, only ER- tumors display a low ER module score,
suggesting that luminal M1 MBC tumors, although posi-
tive by IHC, in fact differ from ER+ FBCs. Luminal M2
MBC tumors also appear to differ from the FBC intrinsic
subgroups, as the correlations between module scores
and ER+ FBC intrinsic subgroups were not recapitulated.
While some similarities to both luminal A and B sub-
groups were observed among luminal M2 tumors, a high
module score for immune response was also seen, a fea-
ture only associated with the HER2 and basal intrinsic
subtypes of FBC. These findings underscore the difficulty
in capturing the complexity of molecular alterations asso-
ciated with MBC subtypes using single protein markers.
To date, only two other studies have attempted to sub-
classify MBC into the major FBC intrinsic subtypes.
Applying IHC and the commonly used protein markers
for FBC subtyping, approximately 80% of the tumors
were classified as luminal A and approximately 20% as
luminal B [41,42]. The discrepancy with our findings is
probably due to the inability of a small number of protein
markers to fully capture the differences in transcriptional
profiles between subtypes. This is illustrated by, for
example, luminal M1 tumors being ER+ by IHC, while
displaying less active ER signaling, more similar to ER-
FBC.
Several studies of FBC have underlined the importance
of regulation of the immune system in ER- and HER2
positive (HER2+) tumors [43-45]. Teschendorf et al.
identified an immune response related seven-gene signa-
ture in ER- tumors correlated to risk of distant metas-
tases [43,44]. Further, Staaf et al. defined a predictor
prognostic of outcome for HER2+ FBC tumors that
included genes associated with immune response, tumor
invasion and metastasis. The better prognosis group dis-
played up-regulation of the immune response and low
invasive ability. Of interest, this predictor also per-
formed well in ER- FBC, but not in ER+/HER2- FBC
[45]. Given the correlation to the immune module in
the luminal M2 subgroup of ER+ MBCs, and the lack of
association with the ER signaling module in the luminal
M1 subgroup, these findings indicate that the two sub-
groups of MBC described herein may constitute two
new subgroups of breast cancer, with unique biological
and clinical features, occurring only in males. Hypotheti-
cally, these patients may require novel treatment strate-
gies. Specifically, despite the majority of tumors in the
luminal M1 subgroup being ER+ they had a low ER sig-
naling module score, suggesting that the ER pathway
may not be active. A recent comprehensive study of
steroid hormone receptors in breast cancer revealed
gender specific differences, suggesting differential hor-
monal dependency [46]. Hence, whether these MBC
patients respond to endocrine therapy like tamoxifen
may be questioned, and needs to be further investigated
in prospective randomized studies. Intriguingly, a recent
study implicated HOXB7, one of the genes up-regulated
in luminal M1 MBC tumors, in rendering FBC cells
resistant to tamoxifen. In addition, high expression of
HOXB7 in tamoxifen treated FBC patients correlated
with poor disease free survival [47].
Importantly, we were able to validate the MBC sub-
groups in an independent dataset [15]; the centroid clas-
sification in this dataset resulted in the same
distribution into the two subgroups as in our dataset,
and unsupervised clustering revealed two stable sub-
groups with similar characteristics as those found in our
dataset. Specifically, the GEX patterns of the centroid
genes were similar and the module scores showed the
same trends in the validation dataset, indicating similar
associations with biological processes. Unfortunately,
however, no information on outcome was available from
that study.
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A comparison between the MBC subgroups and a
dataset representing all intrinsic subgroups of FBC
revealed pronounced differences; 55% and 36% of the
MBC samples were unclassified when applying the Hu
gene centroid and FBC ER+ luminal gene centroid clas-
sifications, respectively. The fraction of unclassified
tumors among FBCs has previously been reported to be
0 to 20% [48]. The GEX patterns based on these genes
also differed between male and female breast tumors,
further indicating that the subgroups of MBC identified
herein are not represented by the intrinsic subgroups of
FBC. When our MBC samples were clustered based on
the ER+ FBC luminal centroid genes, the two MBC sub-
groups were intermixed between the clusters. In support
of this finding, our previous study of genomic profiles in
MBC also revealed that the two MBC subgroups largely
differed from genomic subgroups described in FBC [14].
Although some of the centroid genes in ER+ luminal
FBC may differ between the MBC subgroups, they are
clearly not the most dominant feature.
To further characterize the subgroups and investigate
the clinical relevance of our findings, we investigated
NAT1 and HLA protein levels in a series of 220 MBCs,
as differences in mRNA levels of the corresponding
genes were found between the subgroups. A significantly
worse DMFS was observed for the moderate HLA group
compared with the positive HLA group. Curiously, how-
ever, the HLA negative group initially had a prognosis
similar to the HLA positive group, but late recurrences
resulted in worse long-time survival. Due to the fairly
small sample size and the fact that not many patients
remained alive after eight years, this finding needs to be
interpreted cautiously and more studies are needed to
validate these findings. Interestingly, women with node-
negative breast cancer displaying a mixed HLA class I
expression pattern had a worse prognosis according to a
study by Gudmundsdóttir et al. [49]. Tumors with high
expression of HLA class I can be recognized by T lym-
phocytes of the specific immune system. On the other
hand, tumors lacking expression of HLA class I may be
targeted by NK cells of the non-specific immune system
[50,51]. Tumors with a mixed expression of HLA class I
may thus hypothetically be able to avoid the specific
immune system by displaying too few antigens, while
evading the non-specific immune system by inhibiting
NK cell activity [49,51].
Several studies have reported higher expression of
NAT1 on both protein and mRNA levels in ER+ FBC
compared to ER- FBC [20,52-54], and high expression
of NAT1 has been shown to correlate with better out-
come among ER+ FBCs [55,56]. The NAT1 antibody
used in the present study has been used over the past
20 years with consistent results on cellular localization
[35,36,55], and has been demonstrated to be uniquely
specific following Western blot analysis [52]. However,
there has also been an indication of a nuclear location
[57], which has been linked to turnover of the NAT1
protein. The precise role of the small proportion of
nuclear staining of NAT1 has not been established, but
may well be related to protein turnover and gene regula-
tion. Patients whose tumors were positive for NAT1 dis-
played a significantly better prognosis than those with
NAT1 negative tumors in the present study, a finding
that remained significant in a multivariate analysis. ER
status was not included in the multivariate analysis,
because only seven tumors were ER-. It has, however,
been shown that ER status provides independent prog-
nostic information in MBC [6]. Luminal M2 tumors dis-
played higher NAT1 levels compared to luminal M1
tumors, thus further supporting an association between
the luminal M2 subgroup and better outcome. Bièche et
al. found high NAT1 to be predictive of response to
tamoxifen in women with ER+ breast cancer. In general,
altered tamoxifen metabolism and bioavailability may
contribute to tamoxifen resistance, and the xenobiotic-
metabolizing enzyme NAT1 may be part of this expla-
nation [56]. Unfortunately, we had too few cases to be
able to detect any association between NAT1 and survi-
val among only tamoxifen treated patients, but this find-
ing warrants further investigation and suggests that the
low expression of NAT1 among luminal M1 tumors
may lead to tamoxifen resistance, and that these patients
may hence require alternative treatment approaches.
Conclusions
We have detected two unique and stable subgroups of
MBC with differences in tumor biological features and
outcome, luminal M1 tumors being more aggressive and
associated with worse prognosis, while luminal M2
tumors, on the other hand, displayed up-regulated
immune response and activated ER signaling, generally
favorable features. Importantly, both MBC subgroups
differed from the established intrinsic subgroups of FBC,
indicating that they constitute two novel subgroups of
breast cancer occurring only in males. Consequently,
men diagnosed with breast cancer may require other
management and treatment strategies than women.
Finally, we identified NAT1 as a possible prognostic bio-
marker for MBC, as suggested by NAT1 positivity corre-
sponding to better outcome.
Additional material
Additional file 1: Flow of datasets in the explorative and validation
phases.
Additional file 2: Principal component analyses (PCA). A PCA was
performed and associations between principal components and technical
and biological annotations were evaluated, whereupon a platform-
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specific bias was detected in the main principal component (A). After
adjustment using ComBat [25], no technical variation was found among
the main principal components (B). *NHG, Nottingham histological
grade.
Additional file 3: Enrichment in biological process GO terms of the
genes up-regulated in luminal M1 tumors vs. luminal M2 tumors.
Additional file 4: Enrichment in biological process GO terms of the
genes up-regulated in luminal M2 tumors vs. luminal M1 tumors.
Additional file 5: Heatmaps of the intrinsic genes for female breast
cancer (FBC). Expression of the intrinsic genes according to Hu et al.
(21) in the FBC validation dataset (A) and our male breast cancer (MBC)
dataset (B). Red corresponds to up-regulation and green to down-
regulation.
Additional file 6: Heatmaps of ER positive luminal female breast
cancer centroid genes. Expression of the ER+ luminal FBC centroid
genes in the FBC validation dataset (A) and our MBC dataset (B). Red
corresponds to up-regulation and green to down-regulation.
Additional file 7: Hierarchical clustering (HCL) of male breast cancer
(MBC) with ER positive luminal female breast cancer (FBC) centroid
genes. Unsupervised HCL of our MBC dataset based on the ER+ FBC
centroid genes. The annotations indicate the two MBC subgroups.
Additional file 8: Immunohistochemical detection of NAT1 (A-C) and
HLA (D-F) in paraffin-embedded male breast cancer tumors using a
20x objective. (A) A NAT1 positive tumor with > 75% positive cancer
cells. (B-C) Two NAT1 negative tumors with < = 75% positive cancer
cells. (D) An HLA positive tumor with > 50% positive cancer cells. (E) An
HLA moderate tumor with 5 to 50% positive cancer cells. (F) An HLA
negative tumor with < 5% positive cancer cells.
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